SEMA4F is a membrane-bound glycoprotein of the signaling element receptor family that has been linked to cancer in prior research, including being associated to breast cancer development (39), axonogenesis and neurogenesis in prostate cancer (40), and glioma prognosis (41). This evidence concerns the gene SEMA4F and central nervous system cancer.